Pharmaceutical

KP-910 by Kaken Pharmaceutical for Peripheral Neuropathic Pain: Likelihood of Approval

KP-910is under clinical development by Kaken Pharmaceutical and currently in Phase I for Peripheral Neuropathic Pain.

Jul 1, 2023 - 20:00
KP-910is under clinical development by Kaken Pharmaceutical and currently in Phase I for Peripheral Neuropathic Pain.
Read the original article

Tags:

Previous Article

[177Lu]Lu-rhPSMA-10.1 by Blue Earth Therapeutics for Metastatic Castration-Resis...

Next Article

(Glucagon + insulin human) by Abvance Therapeutics for Hypoglycemia: Likelihood ...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

United Therapeutics gets grant for treatment of pulmona...

Apr 5, 2024

After decades of neglecting women athletes, sport and exercise medicine is finally catching up

After decades of neglecting women athletes, sport and e...

May 19, 2023

Leading innovators in zinc-based medicinal compositions for the pharmaceutical industry

Leading innovators in zinc-based medicinal compositions...

May 8, 2023